Research Blog
What the Research Actually Shows
Plain-English breakdowns of the published studies behind the compounds we carry, with every claim tied back to its source.
Orforglipron: The GLP-1 Pill That Isn't a Peptide Just Passed Its Heart-Safety Test
For twenty years, every GLP-1 drug had the same catch: it was a peptide. Peptides are fragile chains of amino acids, and your stomach treats them like lunch. That's why the famous GLP-1s come as injections. Orforglipron breaks that rule. It isn't a peptide at all. It's a small molecule, closer to an ordinary pill chemical, built to switch on the same GLP-1 receptor.
SS-31: The Mitochondria Peptide That Just Became an FDA-Approved Drug
Most research peptides live their whole lives in the gray zone between "interesting mouse study" and "never heard of it." SS-31 broke out. In September 2025, the FDA approved it as a prescription drug, making it the first medicine ever approved that works by repairing mitochondria from the inside.
SLU-PP-332 vs. SLU-PP-915: What the "Exercise Pill" Research Actually Shows
SLU-PP-332 and SLU-PP-915 flip the same biological switch, but 915 was built to do something 332 can't: work when swallowed. That one difference, oral bioavailability, is why researchers now treat 915 as the more practical molecule.